Drug-Eluting Stents
1
Pipeline Programs
1
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
1
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
1 companies ranked by most advanced pipeline stage
MicroPortChina - Shanghai
2 programs1
3 months DAPTPhase 41 trial
Firehawk sirolimus target eluting coronary stent systemN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
MicroPort3 months DAPT
MicroPortFirehawk sirolimus target eluting coronary stent system
Clinical Trials (2)
Total enrollment: 2,642 patients across 2 trials
Comparison Three vs Twelve Months of Dual Anti-Platelet Therapy After Stent Implantation
Start: Jan 2019Est. completion: Oct 20222,446 patients
Phase 4Unknown
Firehawk™ Coronary Stent System in the Treatment of Coronary Chronic Total Occlusion Lesion(s)
Start: Nov 2017Est. completion: Oct 2023196 patients
N/AUnknown
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.